Ampicillin-Ceftriaxone vs Ampicillin-Gentamicin for Definitive Therapy of Enterococcus faecalis Infective Endocarditis: A Propensity Score-Matched, Retrospective Cohort Analysis

Niyati H Shah, Kathleen A Shutt, Yohei Doi, Niyati H Shah, Kathleen A Shutt, Yohei Doi

Abstract

Background: Ampicillin-ceftriaxone (AC) has emerged as an alternative antibiotic regimen for enterococcal infective endocarditis (EIE) with reduced toxicity compared with ampicillin-gentamicin (AG), but evidence regarding its success in reducing EIE-associated death in the United States is limited.

Methods: We conducted a retrospective, propensity score-matched cohort analysis of EIE patients treated with AC or AG between 2010 and 2017 at 3 hospitals in Pittsburgh, Pennsylvania. We assessed all-cause 90-day mortality as the primary outcome and in-hospital mortality, length of hospital stay, hospital readmissions, adverse events, and relapse of bacteremia as the secondary outcomes.

Results: A total of 190 patients with EIE (100 treated with AC and 90 with AG) were included. Ninety-day mortality was significantly higher with AC than AG (21% vs 8%; P = .02). After propensity score matching, 56 patients in each group remained for the outcomes analysis. Documented aminoglycoside resistance, presence of annular or aortic abscess, and complete pacemaker removal were the significantly different variables between the 2 matched cohorts. We observed no statistically significant difference in 90-day mortality between the 2 treatment groups (11% vs 7%; P = .55). Adverse events were more common in patients treated with AG (25 vs 39; P = .0091), and more patients in the propensity score-matched AG cohort switched antibiotic regimens than in the AC group (10% vs 49%; P < .0001).

Conclusions: Patients treated with AC demonstrate no significant differences in mortality, treatment failure, or bacteremia relapse compared with AG in a propensity score-matched EIE cohort.

Keywords: Enterococcus faecalis; ampicillin; ceftriaxone; gentamicin; infective endocarditis.

© The Author(s) 2021. Published by Oxford University Press on behalf of Infectious Diseases Society of America.

References

    1. Baddour LM, Wilson WR, Bayer AS, et al. ; American Heart Association Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease of the Council on Cardiovascular Disease in the Young, Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and Stroke Council . Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications: a scientific statement for healthcare professionals from the American Heart Association. Circulation 2015; 132:1435–86.
    1. Beganovic M, Luther MK, Rice LB, et al. . A review of combination antimicrobial therapy for Enterococcus faecalis bloodstream infections and infective endocarditis. Clin Infect Dis 2018; 67:303–9.
    1. Gavaldà J, Torres C, Tenorio C, et al. . Efficacy of ampicillin plus ceftriaxone in treatment of experimental endocarditis due to Enterococcus faecalis strains highly resistant to aminoglycosides. Antimicrob Agents Chemother 1999; 43:639–46.
    1. Gavaldá J, Onrubia PL, Gómez MT, et al. . Efficacy of ampicillin combined with ceftriaxone and gentamicin in the treatment of experimental endocarditis due to Enterococcus faecalis with no high-level resistance to aminoglycosides. J Antimicrob Chemother 2003; 52:514–7.
    1. Gavaldà J, Len O, Miró JM, et al. . Brief communication: treatment of Enterococcus faecalis endocarditis with ampicillin plus ceftriaxone. Ann Intern Med 2007; 146:574–9.
    1. Fernández-Hidalgo N, Almirante B, Gavaldà J, et al. . Ampicillin plus ceftriaxone is as effective as ampicillin plus gentamicin for treating Enterococcus faecalis infective endocarditis. Clin Infect Dis 2013; 56:1261–8.
    1. Luther MK, Rice LB, LaPlante KL. Ampicillin in combination with ceftaroline, cefepime, or ceftriaxone demonstrates equivalent activities in a high-inoculum Enterococcus faecalis infection model. Antimicrob Agents Chemother 2016; 60:3178–82.
    1. Araoka H, Kimura M, Yoneyama A. A surveillance of high-level gentamicin-resistant enterococcal bacteremia. J Infect Chemother 2011; 17:433–4.
    1. Tascini C, Doria R, Leonildi A, et al. . Efficacy of the combination ampicillin plus ceftriaxone in the treatment of a case of enterococcal endocarditis due to Enterococcus faecalis highly resistant to gentamicin: efficacy of the “ex vivo” synergism method. J Chemother 2004; 16:400–3.
    1. Peterson SC, Lau TTY, Ensom MHH. Combination of ceftriaxone and ampicillin for the treatment of enterococcal endocarditis: a qualitative systematic review. Ann Pharmacother 2017; 51:496–503.
    1. Pericas JM, Cervera C, del Rio A, et al. ; Hospital Clinic Endocarditis Study Group . Changes in the treatment of Enterococcus faecalis infective endocarditis in Spain in the last 15 years: from ampicillin plus gentamicin to ampicillin plus ceftriaxone. Clin Microbiol Infect 2014; 20:O1075–83.
    1. Mainardi JL, Gutmann L, Acar JF, Goldstein FW. Synergistic effect of amoxicillin and cefotaxime against Enterococcus faecalis. Antimicrob Agents Chemother 1995; 39:1984–7.
    1. Pasticci MB, Mencacci A, Moretti A, et al. . In vitro antimicrobial activity of ampicillin-ceftriaxone and ampicillin-ertapenem combinations against clinical isolates of Enterococcus faecalis with high levels of aminoglycoside resistance. Open Microbiol J 2008; 2:79–84.
    1. Gil-Navarro M, Lopez-Cortes L, Luque-Marquez R, Galvez-Acebal J, de Alarcon-Gonzalez A. Outpatient parenteral antimicrobial therapy in Enterococcus faecalis infective endocarditis. J Clin Pharm Ther 2018; 43:220–3.
    1. Cerón I, Muñoz P, Marín M, et al. . Efficacy of daptomycin in the treatment of enterococcal endocarditis: a 5 year comparison with conventional therapy. J Antimicrob Chemother 2014; 69:1669–74.
    1. El Rafei A, DeSimone DC, Narichania AD, et al. . Comparison of dual β-lactam therapy to penicillin-aminoglycoside combination in treatment of Enterococcus faecalis infective endocarditis. J Infect 2018; 77:398–404.
    1. Harris PA, Taylor R, Thielke R, et al. . Research Electronic Data Capture (REDCap)—a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 2009; 42:377–81.
    1. Harris PA, Taylor R, Minor BL, et al. ; REDCap Consortium . The REDCap consortium: building an international community of software platform partners. J Biomed Inform 2019; 95:103208.
    1. Parsons LS. Performing a 1:n case-control match on propensity score. Available at: . Accessed 26 March 2021.
    1. Olsen MA, Stwalley D, Demont C, Dubberke ER. Clostridium difficile infection increases acute and chronic morbidity and mortality. Infect Control Hosp Epidemiol 2019; 40:65–71.
    1. Pericàs JM, Llopis J, Muñoz P, et al. ; GAMES Investigators . A contemporary picture of enterococcal endocarditis. J Am Coll Cardiol 2020; 75:482–94.
    1. Dahl A, Rasmussen RV, Bundgaard H, et al. . Enterococcus faecalis infective endocarditis: a pilot study of the relationship between duration of gentamicin treatment and outcome. Circulation 2013; 127:1810–7.
    1. Olaison L, Schadewitz K; Swedish Society of Infectious Diseases Quality Assurance Study Group for Endocarditis . Enterococcal endocarditis in Sweden, 1995-1999: can shorter therapy with aminoglycosides be used? Clin Infect Dis 2002; 34:159–66.
    1. Habib G, Lancellotti P, Antunes MJ, et al. ; ESC Scientific Document Group . 2015 ESC guidelines for the management of infective endocarditis: the Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM). Eur Heart J 2015; 36:3075–128.
    1. Iversen K, Ihlemann N, Gill SU, et al. . Partial oral versus intravenous antibiotic treatment of endocarditis. N Engl J Med 2019; 380:415–24.
    1. Beganovic M, Luther MK, Rice LB, et al. . Reply to Koehler et al. Clin Infect Dis 2019; 69:901–2.
    1. Al-Hasan MN, Baddour LM. Resilience of the Pitt bacteremia score: 3 decades and counting. Clin Infect Dis 2020; 70:1834–6.
    1. Li JS, Sexton DJ, Mick N, et al. . Proposed modifications to the Duke criteria for the diagnosis of infective endocarditis. Clin Infect Dis 2000; 30:633–8.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel